Accelerator Directory / Institute Of Cancer Research: Royal Cancer Hospital (the)
We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy. Together with our hospital partner The Royal Marsden NHS Foundation Trust, we are rated in the top four centres for cancer research and treatment worldwide.
As well as being as world-class research institute, the ICR is a higher education institution and a college of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework (REF 2014).
The ICR has charitable status and relies on support from partner organisations, charities, donors and the general public.
The ICR is led by Chief Executive, Professor Paul Workman — an expert in cancer drug discovery.
The majority of ICR employees are directly engaged in research, but there are also important roles in scientific facilities, academic services, IT, fundraising, communication, human resources, and within our Enterprise unit, which negotiates collaborations between ICR scientists and industry.
The Enterprise Unit acts as the technology and knowledge transfer hub for The Institute of Cancer Research, providing the experience and expertise to put in place a wide range of agreements between our scientists and industry.
Although it is not our primary objective, the ICR has been extremely successful in getting a financial return from the commercial exploitation of its research. This income is largely ploughed back into scientific research at the ICR.
We currently have a number of partnering and licensing opportunities in therapeutics, targets, diagnostic biomarkers, devices, and platform or software applications."
- 4573 Biotechnology
- Company Number
- Private Limited by Guarantee/No Share Capital
- Company Age
- 64 years
- June 4, 1954
- Nature of Business
- 72190 - Other research and experimental development on natural sciences and engineering
- Year End
- July 31
- Accounts Due
- April 30, 2019
- Latest Accounts
- July 31, 2017
MARKET: M&A to ScaleUp
MARKET: Legaltech to the Crick
MARKET: Green power to Nanobots
COMPANIES: Ede & Ravenscroft to MRC
MARKET: Biotech Clusters to Ransomware
MARKET: Accelerators to Big Data
MARKET: Foodtech to Smart Cities
MARKET: Circular Economy to Industrial Internet
COMPANIES: Oxford Sciences Innovation to Wimbledon
UK business delegation to China
MARKET: Bad Advice to UK Disruptors
COMPANIES: Metrasens to Otaq
MARKET: Health Tech to Station F, Paris
MARKET: Drones to Deep Tech
MARKETPLACE: media stories 2015-18
MARKET: Gazelles to Industrial Internet
COMPANIES: Perkbox to Revolut
COMPANIES: Itsu to Cambridge Innovation Capital
MARKET: Bioelectronics to Chinese Investment
COMPANIES: Jellycat to Kymab
MARKET: Cash Burn to Workspace
New Year's resolution: visit Station F, Paris
MARKET: Spin-outs to Science Parks
MARKET: Startup Successes to Tech Nation
COMPANIES: Giraffe to Xupes
MARKET: Cyber Security to AI
Wendy Tan White to join BGF Ventures
Queen’s Awards for Enterprise winners 2016
COMPANIES: Alfa to Tokamak Energy
Our news story today: Tumour 'diaries' track cancers' evolutionary history and predict the future… https://t.co/8ODg2HN7xD
If you've been inspired by #CycleToWorkDay today, why not consider a longer cycling challenge to help us make the d… https://t.co/HaCwA7VQOR
Study Discovers First in World Treatment Strategy to Address #BreastCancer Relapse — via @nuigalway:… https://t.co/RgB3Sf9vg8
RT @UoLondon: A very Happy Birthday to our Chancellor, Royal Highness the Princess Royal, Princess Anne. Read her story: https://t.co/66cvB…
In this video from 2016, Dr @AndreaSottoriva talks about his research into predicting how tumours evolve. https://t.co/fYMX8GWygU
This work was supported by the @wellcometrust and @CR_UK. Dr @AndreaSottoriva is a Chris Rokos Fellow in Evolution and Cancer.
NEWS: Scientists at the ICR, @UGI_at_UCL and @QMBCI have developed a complex mathematical model that uses a snapsho… https://t.co/SYfCPcTibS
A fantastic interview with @TheCrick and @CR_UK's Professor Karen Vousden, who reflects on her career - including h… https://t.co/7JG1bd6ufz
Read about our innovative 'Will for Free' programme and how it helps fund vital research https://t.co/V2fVnNvFt0 https://t.co/lrKflFZVom